All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The brain is the centre of the nervous system in all vertebrates, and is responsible for controlling all bodily functions ranging from walking and talking, to heart rate and endocrine function. In addition to this diseases of the brain and central nervous system represent a major cause of global morbidity and mortality, with over 600 recognised neurological diseases \[[@pone.0122883.ref001]\] including developmental disorders such as Down syndrome and autism spectrum disorders \[[@pone.0122883.ref002]--[@pone.0122883.ref003]\], seizure disorders like epilepsy \[[@pone.0122883.ref004]\] and neurodegenerative disorders including Alzheimer's and Parkinsons diseases \[[@pone.0122883.ref005]--[@pone.0122883.ref008]\]. Despite the importance of the brain and the pathological burden associated with it, we are still relatively ignorant of its mechanisms and it is hoped that developing a better understanding of cerebral metabolism will help to begin unlocking the secrets of the brain. Arguably, the biggest challenges of working with both human and animal brain tissue are twofold, firstly the small amounts/preciousness due to inaccessibility of sample material and secondly reproducible extraction of metabolites from the sample tissues. These obstacles make the development of analytical approaches that maximise the metabolites that can be reproducibly measured from small tissue samples an important challenge.

Metabolomics is the unbiased analysis of the composition of small molecule metabolites in a given biological tissue or fluid, under a specific set of environmental conditions \[[@pone.0122883.ref009]--[@pone.0122883.ref010]\]. Due to the wide range of concentrations at which these metabolites are present and their diverse physiochemical properties it is challenging to obtain comprehensive analysis of all metabolite classes using a single method \[[@pone.0122883.ref011]--[@pone.0122883.ref014]\]. Therefore many metabolomic approaches that aim to maximise metabolite coverage utilise a combination of analytical platforms including liquid chromatography---mass spectrometry (LC-MS), nuclear magnetic resonance (NMR) and gas chromatography---mass spectrometry (GC-MS) \[[@pone.0122883.ref011], [@pone.0122883.ref015]--[@pone.0122883.ref016]\]. These multi-platform approaches will measure metabolites with a wide range of concentrations and physiochemical properties, however the downside to increasing metabolite coverage will be a significant increase in the amount of tissue required.

LC-MS is one of the most widely used analytical techniques for metabolite fingerprinting and has been used to analyse a range of metabolite classes in a variety of biological matrices \[[@pone.0122883.ref017]--[@pone.0122883.ref020]\]. One of the major advantages of this approach is that it separates complex sample mixtures into its constituent components prior to mass spectral analysis. Separation enables the discrimination of some isobaric compounds which mass spectrometry alone cannot do, it also helps to reduce matrix effects in the ionisation chamber such as ionisation suppression in which different components of the matrix compete to be ionised resulting in a suppressed metabolite signal and incorrect metabolite quantitation \[[@pone.0122883.ref021]--[@pone.0122883.ref024]\]. However, one important limitation is that physiochemical properties of metabolites are diverse, and a single chromatographic technique cannot separate thousands of metabolites. For example reversed phase chromatography will separate non-polar metabolites such as lipids, but not separate polar compounds like amino acids \[[@pone.0122883.ref013]\]. This means that all of the polar metabolites will co-elute at the start of the chromatogram, with many not being measured correctly due to ion suppression. Therefore, as a result multiple chromatographic separation techniques are required to achieve a broad coverage of the metabolome. Sample preparation for LC-MS metabolite fingerprinting usually involves a solvent based (usually methanol, ethanol or acetonitrile) protein precipitation \[[@pone.0122883.ref025]\] to reduce surface absorption and protein-metabolite interactions. Different chromatographic conditions require distinct sample preparations increasing analysis time, analytical variability and the amount of sample material required. A main obstacle in metabolomics is metabolite identification, metabolite features measured need to be translated to chemical identities or metabolites that can give biological information.

Metabolite annotation has repeatedly been identified as a significant bottleneck in mass spectrometry untargeted workflows \[[@pone.0122883.ref026]--[@pone.0122883.ref027]\]. There are several challenges that make metabolite annotation difficult, the first of which is that there is up to an estimated 200,000 distinct metabolites \[[@pone.0122883.ref010]\] less than 50% of which have been structurally identified. Many metabolites, especially esoteric compounds, have unknown structure, so complete identification can only be done by compound synthesis, hence sharing of in-house databases is unusual. Secondly whilst fragmentation patterns are used for identification, this is an expert field and good quality fragmentation is not always possible.

To date there has been a number of metabolomic studies that have looked at the metabolite composition of brain tissue. Salek *et al*. \[[@pone.0122883.ref028]\] used 1H-NMR to measure the metabolite composition in the hippocampus, cortex, frontal cortex, midbrain and cerebellum of CRND8 mice identifying 23 metabolites from tissue samples ranging in mass from 10--50mg. In humans, brain tissue is in short supply and to date only small numbers (n = 10--15) with reversed phase fingerprinting have been profiled. However two groups were able to make important contributions, Graham *et al*. \[[@pone.0122883.ref029]\] used ≈5g of human post mortem brain and UPLC-ToF to develop a method that detected 1,264 metabolic features, with 10 features shown to be correlated to AD. Koichi *et al*. \[[@pone.0122883.ref030]\] also used UPLC-ToF metabolomics of human brain and found spermine and spermidine to be increased in AD pathology.

Therefore, this study aimed to obtain both polar and non-polar metabolites from a single small sample of brain tissue. For this HILIC together with reversed phase (RP) methods were investigated. Another aim was to provide the means for metabolite identification with the method, the data generated is the basal metabolome in rat cerebellum that can be applied in clinical investigations.

Materials and Methods {#sec002}
=====================

Chemicals and Reagents {#sec003}
----------------------

All solvents, water, methanol, acetonitrile, ammonium formate, formic acid and methyl tertiary butyl ether (MTBE), were LC-MS grade purchased from Sigma-Aldrich. Four internal standards, heptadecanoic acid (≥ 98% purity), tripentadecanoin (≥ 98% purity) for the reversed phase, and L-serine^13^C~3~ ^15^N (95%) and L-valine^13^C~5~ ^15^N (95%) for HILIC were purchased from Sigma-Aldrich. In-vial dual extractions were performed in amber glass HPLC vials with fixed 0.4 mL inserts (Chromacol: Welwyn Garden City, UK).

Samples {#sec004}
-------

Experimental tissue material was obtained from the cerebellum of adult male (Sprague-Dawley) rats obtained from Harlan Laboratories UK. The animals were euthanized in the Biomedical services unit, King's College London by inducing carbon dioxide (CO~2~) anoxia followed by cervical dislocation as per Schedule 1 of the Animal (scientific procedures) Act of 1986. All animal procedures were approved by local animal welfare and the Ethics Review Body (King's College London). The cerebellum was isolated according to the Springer protocol for the dissection of rodent brain regions \[[@pone.0122883.ref031]\], samples were weighed and subsequently stored at -80°C. The cerebellum was sectioned on sterile glass slides (Thermo Scientific, Menzel-Glazer slides) using a sterile scalpel, both scalpel and slide were cooled in liquid nitrogen to reduce sample thawing during sectioning. Sectioned tissue samples were transferred to Eppendorf tubes containing a clean, pre-cooled, 5mm stainless steel ball bearing.

Experimental Design {#sec005}
-------------------

In this study two primary experiments were performed to assess the precision and sensitivity of the IVDE, instrument methods and tissue homogenisation as well as to determine the effect of sample mass on metabolite recovery. The first experiment was designed to assess the combined variability of the IVDE and instrument methods. This was done by homogenising a single piece (18mg) of rat cerebellum, removing sample mass and tissue homogenisation as sources of variability. The homogenate was split into 7 aliquots of 50μl which underwent parallel extractions prior to injection on both HILIC and reversed phase methods ([Fig 1A](#pone.0122883.g001){ref-type="fig"}). The second experiment was designed to assess the effect of the mass of tissue extracted and tissue homegenistation on method sensitivity and precision. Four Sprague-Drawly rat brain were obtained and this material was used to perform Experiment 2. To do this 15 tissue samples ranging from 3--17mg were homogenised and extracted in parallel prior to analysis ([Fig 1B](#pone.0122883.g001){ref-type="fig"}). Sensitivity was assessed in terms of the number of metabolite features that are routinely detected, whilst precision will be assessed in terms of the variability (coefficient of variation) of the abundance of internal standard and metabolite peaks as well as the degree of compositional similarity between samples as determined principal component analysis (PCA). A graphical description of the analytical workflow used in this study is shown in [Fig 2](#pone.0122883.g002){ref-type="fig"}.

![Graphical representation of the experimental designs used.\
A) experiment 1, a single 18mg brain section was homogenised then 7 parallel extractions were performed on 50μl aliquots of homogenate. B) Experiment 2, brain sections ranging from 3--17mg were homogenised and extracted parallel.](pone.0122883.g001){#pone.0122883.g001}

![Applied analytical pipeline.\
Shows the seven steps from tissue sectioning to IVDE and onto data processing and multivariate analysis of variation.](pone.0122883.g002){#pone.0122883.g002}

Tissue homogenisation {#sec006}
---------------------

Prior to homogenisation 20μl of methanol and 5μl of HILIC internal standard cocktail (2.5mM L-serine^13^C~3~ ^15^N and L-valine^13^C~5~ ^15^N in methanol:water (4:1)) was added per milligram of sample material. The tissue was then homogenised using a Tissuelyzer(Qiagen) in 10 cycles of 30 seconds at 25 Hz, subsequently a 50ul aliquot of homogenate was transferred to a Chromacol HPLC vial (400μl fixed insert).

In-vial dual extraction of brain tissue {#sec007}
---------------------------------------

Subsequently 10μl of water was added to the homogenate, vials were then vortexed for 5 minutes, after which 250μl of MTBE containing Tripentadecanoin (10 μg/ml) and Heptadecanoic acid (10 μg/ml) was added after which samples were again vortexed at room temperature for 60 minutes. Following the addition of a further 40μl of water containing 0.15mM ammonium formate to enhance phase separation, samples were then centrifuged at 2500×g for 30 minutes at 4°C. This resulted in a clear separation of MTBE (upper) and aqueous (lower) phases, with protein precipitate aggregated at the bottom of the vial. Quality control samples were created by pooling excess tissue homogenate from biological samples (after a 50μl aliquot had been taken), this excess homogenate was then split into 50μl aliquots for in-vial extraction.

LC-MS analysis of IVDE non-aqueous phase {#sec008}
----------------------------------------

LC-MS analysis was performed on a Waters Acquity ultra performance liquid chromatogram (UPLC) system coupled to a Waters Premier quadrupole time-of-flight (Q-Tof) mass spectrometer (Waters, Milford, MA, USA). The needle height in the auto-sampler was set to 13mm, with 5μl of sample extract injected onto an Agilent Poroshell 120 EC-C8 column (150mm × 2.1mm, 2.7 μm). Separation was performed at 55°C with a flow-rate of 0.5 ml/min using 10mM ammonium format in water (mobile phase A) and 10mM ammonium format in methanol (mobile phase B). For analysis in the positive mode, the gradient started at 80% mobile phase B increasing linearly to 96% B in 23 minutes and was held until 45 minutes then the gradient was increased to 100% by 46 minutes until 49 minutes. Initial conditions were restored in 2 minutes ahead of 7 minutes of column re-equilibration. For analysis in the negative ionisation mode the gradient started at 75% B increasing linearly to 96% B at 23 minutes, then increasing further to 100% B by 35 minutes, initial conditions were restored to allow 7 minutes of column re-equilibration. In the positive mode, a capillary voltage of 3.2 kV and a cone voltage of 45V was applied. Data was collected between 50 and 1000*m/z*, the desolvation gas flow was 400 L/hour and the source temperature was 120°C. In the negative mode, a capillary voltage of 2.6 kV and a cone voltage of 45 V were used. Desolvation gas flow and source temperature were fixed at 800 L/h and 350°C, respectively. All analyses were acquired using the lock spray to ensure accuracy and reproducibility; A reference solution (leucine-enkephalin) was used as lock mass (*m/z* 556.2771 and 278.1141) at a concentration of 200 ng/mL to update accurate mass data values and a flow rate of 10 μL/min. Data were collected in the centroid mode over the mass range *m/z* 50--1000 with an acquisition time of 0.1 seconds a scan.

LC-MS analysis of IVDE aqueous phase {#sec009}
------------------------------------

The auto sampler needle height was set at 2mm, with analysis of 5μl of aqueous phase extract being analysed on a Merck Sequant Zic-HILIC column (150 × 4.6mm, 5μm particle size) coupled to a Merck Sequant guard column (20 × 2.1mm). A 40 minute room temperature gradient (0.3ml/min) was applied using 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). The gradient started at 80% mobile phase B, followed by a linear reduction to 20% mobile phase B after 30 minutes, initial conditions were restored to allow 10 minutes of column re-equilibration. Mass spectral data was acquired between 75--1000 Daltons in both positive and negative ionisation modes. The applied mass spectrometry conditions were the same as for the reversed phase method.

Data processing and metabolite identification {#sec010}
---------------------------------------------

The generated data was processed using MarkerLynx (Masslynx 4.1 Waters, USA) which provides automated peak detection based on peak alignment and normalization to total peak area. The reversed phase data were processed with a mass tolerance of 0.01 daltons (Da), a mass window of 0.05Da, and a retention time window of 12 seconds and a peak width of 10 seconds. The HILIC data was processed with a mass tolerance of 0.01 daltons (Da), a mass window of 0.05 Da, retention time window 18 seconds, and peak width of 20 seconds. Processed data was evaluated using principal component analysis (PCA) performed in SIMCA 13.0.3 (Umetrics, Umeå, Sweden). The data in all of the generated PCA models was logarithmically transformed (base 10) and scaled to unit variance (UV). The performance of the PCA models generated was assessed based on the cumulative correlation coefficients (R^2^X\[cum\]), and predictive performance based on seven-fold cross validation (Q^2^\[cum\]). Hotelling's T^2^ plots were used to assess the departure of samples from the origin in the model plane, which will show the distance of a sample to a calculated average observation (i.e. an average metabolite composition). The DModX plots corresponds to the residual standard deviation of an observation in the x-variables, it was used to assess the distance of an observation to the fitted model.

Metabolite annotation was performed by searching the *m/z* of measured metabolite features in a range of publicly accessible metabolite databases including the human metabolome database (HMDB), METLIN and LipidMaps. Once potential metabolites had been identified it was confirmed by matching the fragmentation pattern of the peak being annotated to the fragmentation pattern shown for given metabolites in the literature and standard compounds. In addition some peaks in the reversed phase method were annotated by comparing the *m/z* and retention time of metabolite features to metabolite features previously annotated in Whiley *et al*. \[[@pone.0122883.ref032]\].

Results/Discussion {#sec011}
==================

Assessing the effect of IVDE and LC-MS on method performance and precision (Experiment 1) {#sec012}
-----------------------------------------------------------------------------------------

The first step in assessing the precision of the in-vial dual extraction (IVDE) and both the reversed phase and HILIC methods was to determine the recovery for four internal standards ([Fig 3](#pone.0122883.g003){ref-type="fig"}). In the HILIC method both internal standards were measured in both the positive and negative ionisation modes. In the positive data the recovery of internal standards are highly consistent with coefficient of variation (CV) of 2.4% and 3.7% ([Fig 3B](#pone.0122883.g003){ref-type="fig"}) for the serine and valine standards respectively. In the negative mode, recovery is more variable than the positive mode with CV's of 9.1% and 5.7% ([Fig 3C](#pone.0122883.g003){ref-type="fig"}) for serine and valine respectively. In the reversed phase method heptadecanoic acid was measured in the negative mode and tripentsdecanoin was measured in the positive. The recovery of both standards was consistent with CV's of 2.5% and 4.4% for heptadecanoic acid and tripentadenanoin respectively. The standard recoveries suggests that the IVDE and both HILIC and reversed phase methods have good precision with all internal standard measurements having CV's less than 15% \[[@pone.0122883.ref033]\], with mass spectrometry in the negative mode adding more variability than the positive mode.

![Recoveries of HILIC and reversed phase internal standards in experiment 1.\
A) plot of intensity of reversed phase internal standards Heptadecanoic acid (negative) and Tripentadecanoin (positive), B) plot of intensity of HILIC internal standards in positive ionisation mode, C) plot of intensity of HILIC internal standards in negative ionisation mode, D) average intensity and coefficient of variance of all internal standards.](pone.0122883.g003){#pone.0122883.g003}

The next step in determining the methods performance was to identify the number of metabolite features measured following HILIC and reversed phase separation and to assess the precision of these peaks. This was done by initially identifying the features present in all samples, then identifying those features measured in at least of 85% of samples, with a minimum cut off of peaks present in at least 70% of samples analysed (Tables [1](#pone.0122883.t001){ref-type="table"} and [2](#pone.0122883.t002){ref-type="table"}). In total 5,841 metabolite features were measured in 100% of samples for both the HILIC (3713 metabolite features) and reversed phase (2128 metabolite features) methods. When a 70% sample presence cut off was applied, 12,274 metabolite features were identified with 6,570 and 5,704 metabolite features measured in the HILIC and reversed phase methods respectively. The measured metabolite features show good precision with 3,468 of the 5,841 (59.4%) of peaks seen in 100% of samples, and 6,362 of the 12,274 (51.8%) of the peaks measured in at least 70% of samples have CV's of \<15%. In general the features with CV's of ≥15% are lower in abundance, with peaks at CV's \<15% with an average abundance 6.62 and peaks with CV's ≥15% having an average of 1.93 potentially accounting for the lower precision. It is also interesting to note that the metabolite features that are measured in all samples have a higher average abundance (4.76) than those measured in 85% (2.04) and 70% (1.83). This is due to these groups possessing more peaks that are close to the limit of detection (LOD) with the peak falling below the LOD in some samples accounting for the missing values.

10.1371/journal.pone.0122883.t001

###### Measured metabolite features in the HILIC method in experiment 1.

![](pone.0122883.t001){#pone.0122883.t001g}

                                                          HILIC Positive   HILIC Negative   HILIC Total                                      
  ------------------------------------------------------- ---------------- ---------------- ------------- ------ ------ ------ ------ ------ ------
  **\< 5** [^**b**^](#t001fn003){ref-type="table-fn"}     141              155              170           103    113    127    244    268    297
  **5--10** [^**b**^](#t001fn003){ref-type="table-fn"}    416              507              598           605    668    726    1021   1175   1324
  **10--15** [^**b**^](#t001fn003){ref-type="table-fn"}   305              436              582           460    618    726    765    1054   1308
  **15--30** [^**b**^](#t001fn003){ref-type="table-fn"}   417              635              889           803    1204   1539   1220   1839   2428
  **\> 30** [^**b**^](#t001fn003){ref-type="table-fn"}    149              286              406           314    540    807    463    826    1213
  **Total**                                               1428             2019             2646          2285   3143   3925   3713   5162   6570

Showing the number of metabolite peaks identified and their relative variability in 100%, 85% and 70% of 7 sample replicates.

^a^ percentage of samples a peak is detected in

^b^ coefficient of variance of peak intensity between samples.

10.1371/journal.pone.0122883.t002

###### Measured metabolite features in the reversed phase method in experiment 1.

![](pone.0122883.t002){#pone.0122883.t002g}

                                                          RP Positive   RP Negative   RP Total                                      
  ------------------------------------------------------- ------------- ------------- ---------- ------ ------ ------ ------ ------ ------
  **\< 5** [^**b**^](#t002fn003){ref-type="table-fn"}     124           261           278        202    253    455    326    514    733
  **5--10** [^**b**^](#t002fn003){ref-type="table-fn"}    193           418           450        504    628    1112   697    1046   1562
  **10--15** [^**b**^](#t002fn003){ref-type="table-fn"}   69            115           197        346    418    941    415    533    1138
  **15--30** [^**b**^](#t002fn003){ref-type="table-fn"}   112           246           329        402    484    1009   514    730    1338
  **\> 30** [^**b**^](#t002fn003){ref-type="table-fn"}    50            134           226        126    340    707    176    474    933
  **Total**                                               548           1174          1480       1580   2123   4224   2128   3297   5704

Showing the number of metabolite peaks identified and their relative variability in 100%, 85% and 70% of 7 sample replicates.

^a^ percentage of samples a peak is detected in

^b^ coefficient of variance of peak intensity between samples.

Having considered the behaviour of individual metabolite peaks, the final step in assessing the method performance is to look at the similarity of the overall composition of the analysed samples. Principal component analysis (PCA) was performed on all 12,274 metabolite features that were identified in at least 70% of samples ([Fig 4](#pone.0122883.g004){ref-type="fig"}). This PCA revealed little structure within the data with the first component accounting for only 25.3% of the total variability with a predictive performance of Q^2^ = -0.10, with the first two components accounting for just 43.9% of variability with a predictive performance of Q^2^ = -0.21. The distance of a samples metabolite composition to a calculated average composition was assessed using the Hotelling's T^2^ range plot ([Fig 4B](#pone.0122883.g004){ref-type="fig"}). This plot shows that all of the samples are compositionally similar both to each other and the calculated average, with all samples having a T^2^ of \< 5 with the 95% confidence interval set at 13.88. The distance of samples to the model was assessed using the DModX plot ([Fig 4C](#pone.0122883.g004){ref-type="fig"}), which shows that the samples have a low residual of difference to the fitted model with all of the observations falling below the Dcritical(0.05) threshold. This combined with the Hotelling's T^2^ show that all of the samples are compositionally similar and that there are no outliers to the model.

![Principal component analysis (components = 2, R^2^X -- 0.439, Q^2^--0.210) of metabolite features identified in at least 70% of samples in experiment 1.\
A) scores plot and B) Hotelling's T^2^ and C) DModX plot, showing that sample mass has no effect on overall metabolite composition.](pone.0122883.g004){#pone.0122883.g004}

Assessing the effect of tissue homogenisation and sample mass on method performance and precision (Experiment 2) {#sec013}
----------------------------------------------------------------------------------------------------------------

As with assessing the performance of the IVDE and instrument methods, the first step in assessing the effect of tissue homogenisation and sample mass is to look at the recovery of the internal standards. As in experiment 1 both HILIC internal standards are seen in positive and negative ionisation modes ([Fig 5B and 5C](#pone.0122883.g005){ref-type="fig"}). In the positive mode the CV's of the internal standard recoveries were 13.5% and 14.7% for serine and valine respectively. In the negative mode CV's of the internal standard recoveries were 14.9% and 14.4% for serine and valine respectively. In the reversed phase data heptadecanoic acid is measured in the negative mode with a CV of 13.4%, and tripentadecanoin was measured in the positive mode with a CV of 3.8%. The recovery of the HILIC internal standards is more variable in these samples than in experiment 1, suggesting that the tissue homogenisation step is contributing significantly to analytical variability. This is further supported by no increase in the variability of tripentadecanoin which is spiked into the sample after tissue homogenisation. The recovery of the HILIC internal standards in the quality control samples, which are pooled after tissue homogenisation, were more consistent than in the analytical samples, and comparable with experiment 1 with CV's of 3.8% and 4.8% in positive and 5.3% and 7.1% in negative for serine and valine respectively, further supporting the hypothesis that tissue homogenisation is contributing significantly to the observed variability. With the increased CV's showing that tissue homogenisation is contributing to an increase in data variability, it is important to assess the effect of the extracted tissue volume on the recovery of the internal standards. Spearman's correlation was used to assess the relationship between standard recovery and sample mass, this analysis revealed no significant correlations showing that internal standard recovery is independent of the sample mass extracted.

![Recoveries of HILIC and reversed phase internal standards in experiment 2.\
A) plot of intensity of reversed phase internal standards Heptsdecanoic acid (negative) and Tripentadecanoin (positive), B) plot of intensity of HILIC internal standards in positive ionisation mode, C) plot of intensity of HILIC internal standards in negative ionisation mode, D) average intensity and coefficient of variance of all internal standards.](pone.0122883.g005){#pone.0122883.g005}

The next step in assessing the method performance is to determine the number of metabolite features measured and the precision of these peaks. As in experiment 1 this was initially done by identifying peaks that were measured in all samples, working down to a cut off of peaks present in at least 73% of samples. In total 4,021 peaks were measured in 100% of samples, with 2,838 and 1,183 measured in HILIC ([Table 3](#pone.0122883.t003){ref-type="table"}) and reversed phase ([Table 4](#pone.0122883.t004){ref-type="table"}) methods respectively, 10,934 peaks measured in 73% of samples with 6,737 and 4,197 measured in HILIC and reversed phase data respectively. The precision of the measured peaks is lower than was seen in experiment 1 with 1,726 of 4,021 (43.7%) of the peaks seen in 100% of samples and 3,151 of 10,934 (28.8%) of peaks seen in 70% of samples having CV's of \<15%. The finding of higher sample to sample variability of the measured metabolite features lends further support to the hypothesis of tissue homogenisation as a source of variability within the method. A transformation of the HILIC data to correct for the variability introduced during tissue homogenisation was performed by normalising peak intensity to an average of the abundance of the two internal standards, however this correction did not improve precision of the measured metabolite peaks ([S1 Table](#pone.0122883.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0122883.t003

###### Measured metabolite features in the HILIC method in experiment 2.

![](pone.0122883.t003){#pone.0122883.t003g}

                                                          HILIC Positive                                    HILIC Negative                                   HILIC Total                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ------------------------------------------------------- ------------------------------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------ ------------------------------------------------
  **%RSD**                                                **100%** [^a^](#t003fn002){ref-type="table-fn"}   **93%** [^a^](#t003fn002){ref-type="table-fn"}   **87%** [^a^](#t003fn002){ref-type="table-fn"}   **80%** [^a^](#t003fn002){ref-type="table-fn"}   **73%** [^a^](#t003fn002){ref-type="table-fn"}   **100%** [^a^](#t003fn002){ref-type="table-fn"}   **93%** [^a^](#t003fn002){ref-type="table-fn"}   **87%** [^a^](#t003fn002){ref-type="table-fn"}   **80%** [^a^](#t003fn002){ref-type="table-fn"}   **73%** [^a^](#t003fn002){ref-type="table-fn"}   **100%** [^a^](#t003fn002){ref-type="table-fn"}   **93%** [^a^](#t003fn002){ref-type="table-fn"}   **87%** [^a^](#t003fn002){ref-type="table-fn"}   **80%** [^a^](#t003fn002){ref-type="table-fn"}   **73%** [^a^](#t003fn002){ref-type="table-fn"}
  **\< 5** [^**b**^](#t003fn003){ref-type="table-fn"}     38                                                49                                               56                                               68                                               81                                               33                                                39                                               44                                               55                                               61                                               71                                                88                                               100                                              123                                              142
  **5--10** [^**b**^](#t003fn003){ref-type="table-fn"}    322                                               408                                              431                                              467                                              509                                              217                                               302                                              283                                              344                                              372                                              539                                               710                                              714                                              811                                              881
  **10--15** [^**b**^](#t003fn003){ref-type="table-fn"}   426                                               566                                              601                                              644                                              685                                              222                                               353                                              386                                              495                                              566                                              648                                               919                                              987                                              1139                                             1251
  **15--30** [^**b**^](#t003fn003){ref-type="table-fn"}   406                                               583                                              742                                              793                                              884                                              501                                               751                                              1115                                             1142                                             1348                                             907                                               1334                                             1857                                             1935                                             2232
  **\> 30** [^**b**^](#t003fn003){ref-type="table-fn"}    454                                               610                                              827                                              1078                                             1254                                             219                                               362                                              514                                              735                                              977                                              673                                               972                                              1341                                             1813                                             2231
  **Total**                                               1646                                              2216                                             2657                                             3050                                             3413                                             1192                                              1807                                             2342                                             2771                                             3324                                             2838                                              4023                                             4999                                             5821                                             6737

Showing the number of metabolite peaks identified and their relative variability in 100%, 93%, 87%, 80% and 73% of 15 sample replicates.

^a^ percentage of samples a peak is detected in

^b^ coefficient of variance of peak intensity between samples.

10.1371/journal.pone.0122883.t004

###### Measured metabolite features in the reversed phase method in experiment 2.

![](pone.0122883.t004){#pone.0122883.t004g}

                                                          RP Positive   RP Negative   RP Total                                                                            
  ------------------------------------------------------- ------------- ------------- ---------- ----- ----- ----- ----- ------ ------ ------ ------ ------ ------ ------ ------
  **\< 5** [^**b**^](#t004fn003){ref-type="table-fn"}     168           184           195        229   238   9     9     14     14     14     177    193    209    243    252
  **5--10** [^**b**^](#t004fn003){ref-type="table-fn"}    203           213           220        231   235   7     11    30     38     38     210    224    250    269    273
  **10--15** [^**b**^](#t004fn003){ref-type="table-fn"}   65            72            93         140   156   46    81    127    191    196    111    153    220    331    352
  **15--30** [^**b**^](#t004fn003){ref-type="table-fn"}   103           119           147        166   182   267   271   754    1314   1363   370    390    901    1480   1545
  **\> 30** [^**b**^](#t004fn003){ref-type="table-fn"}    49            62            89         135   184   266   388   901    1524   1591   315    450    990    1659   1775
  **Total**                                               588           650           744        901   995   595   760   1826   3081   3202   1183   1410   2570   3982   4197

Showing the number of metabolite peaks identified and their relative variability in 100%, 93%, 87%, 80% and 73% of 15 sample replicates.

^a^ percentage of samples a peak is detected in

^b^ coefficient of variance of peak intensity between samples.

Having considered metabolite features individually it is important to consider the composition of samples as a whole. As in experiment 1 PCA was applied to all metabolite features that were measured in at least 73% of samples ([Fig 6](#pone.0122883.g006){ref-type="fig"}). The analysis revealed little structure within the data with the first component accounting for only 22.3% of total variability with a poor predictive performance of Q^2^ = 0.07, with the second component only explaining a further 13.1% of variability (Q^2^ = 0.05) ([Fig 6A](#pone.0122883.g006){ref-type="fig"}). The Hotelling's T^2^ plot ([Fig 6B](#pone.0122883.g006){ref-type="fig"}) shows that all samples fall within the 95% confidence interval (T^2^ = 8.19), with all bar one sample having a T^2^ \< 4 demonstrating that the samples are compositionally similar both to each other and to the calculated average. The DModX plot ([Fig 6C](#pone.0122883.g006){ref-type="fig"}) shows that all samples have a low residual of difference to the fitted model with all of the observations falling below the Dcritical(0.05) threshold. This combined with the Hotelling's T^2^ plot show that all samples are compositionally similar and that there are no outliers to the model.

![Principal component analysis of samples (components = 2, R^2^X 0.354, Q^2^ 0.049) performed on metabolite features identified in at least 73% of samples in experiment 2.\
A) scores plot where point labels represent sample mass B) Hotelling's T^2^ and C) DModX plot of analytical samples, showing that sample mass has no effect on overall metabolite composition.](pone.0122883.g006){#pone.0122883.g006}

Whilst all samples are compositionally similar it is important to determine the effect of the extracted tissue mass on metabolite composition. Looking at the PCA scores plot ([Fig 6A](#pone.0122883.g006){ref-type="fig"}) it can be seen that there is no bias in the distribution of samples based on the tissue mass, with low and high mass samples clustering together within the plot showing that they possess high levels of compositional similarity. As well as looking at the effect of sample mass on the compositional similarity it is important to assess its effect on the abundance of individual metabolites. [Fig 7](#pone.0122883.g007){ref-type="fig"} shows the abundance of 9 annotated metabolites from both HILIC and reversed phase methods plotted against the tissue mass, these plots show no relationship between metabolite abundance and sample mass, with the strongest correlation being for glutamate (r = -0.24). This data shows that using between 3--17mg of sample material has no effect on the overall sample composition or the abundance of individual metabolites, showing this method can provide broad metabolite coverage when sample material is limited.

![Plots of sample mass in milligrams against intensity for 9 annotated metabolites.\
A) taurine B) hypoxanthine C) glutamate D) pantothenate E) aspartate F) glcosylceramide (36:1) G) phosphatidylethanolamine (38:4) H) ceramide (38:1) I) triglyceride (48:3).](pone.0122883.g007){#pone.0122883.g007}

Annotated metabolites {#sec014}
---------------------

Having optimised the sensitivity and reproducibility of the metabolite features measured by the analytical method, the final step is to demonstrate its biological relevance by linking the data directly to metabolism by annotating metabolites from a variety of chemical classes and across a range of concentrations. To do these 200 metabolites, 100 from both the HILIC and reversed phase methods were annotated (Tables [5](#pone.0122883.t005){ref-type="table"} and [6](#pone.0122883.t006){ref-type="table"}). The annotated metabolites come from a wide range of metabolite classes including amino acids, purines, phospholipids and glycerides, across 3.5 orders of magnitude ranging in abundance from 0.1 to 576.9. There is limited overlap between the two analytical methods with no identified metabolites in common, this limited overlap demonstrates the necessity of using complimentary separation techniques like HILIC and reversed phase chromatography to obtain a comprehensive view of all of chemical space. These annotations enable the method to be easily compared as basal metabolite abundance in the rat's healthy cerebellum and provide valuable information allowing the method to be accurately replicated by other laboratories.

10.1371/journal.pone.0122883.t005

###### Metabolites annotated from the HILIC method.

![](pone.0122883.t005){#pone.0122883.t005g}

  Name                         Formula       Molecular Weight (Da)   Retention time (Mins)   Intensity   
  ---------------------------- ------------- ----------------------- ----------------------- ----------- -------
  Acetylalanine                C5H9NO3       131.0582                15.56                   6.2         \-
  Acetylaspartate              C6H9NO5       175.0480                7.66                    6.4         56.2
  Acetylaspartylglutamate      C11H16N2O8    304.0906                8.38                    7.2         28.6
  Acetylcarnitine              C9H17NO4      203.1157                14.08                   27.0        0.4
  Acetylneuraminate            C11H19NO9     309.1059                23.88                   0.4         \-
  Acetylserine                 C5H9NO4       147.0531                8.31                    \-          22.3
  Adenosine                    C10H13N5O4    267.0967                12.92                   33.3        \-
  Adenosine monophosphate      C10H14N5O7P   347.0630                15.60                   6.2         \-
  Adrenaline                   C9H13NO3      183.0895                6.74                    2.9         \-
  Alanine                      C3H7NO2       89.0476                 16.61                   184.5       39.2
  Aminobutyrate                C4H9NO2       103.0633                16.25                   \-          84.5
  Arachidonoyl glycidol        C23H36O3      360.2664                5.01                    7.8         \-
  Arginine                     C6H14N4O2     174.1116                26.47                   40.9        7.4
  Ascorbate                    C6H8O6        176.0320                10.72                   4.2         69.1
  Asparagine                   C4H8N2O3      132.0534                17.01                   \-          1.4
  Aspartate                    C4H7NO4       133.0375                7.81                    109.2       33.6
  Butyrlcarnitine              C11H21NO4     231.1470                12.11                   1.7         \-
  Carnitine                    C7H15NO3      161.1051                17.06                   135.5       \-
  Carnosine                    C9H14N4O3     226.1065                28.8                    2.1         \-
  Citrate                      C6H8O7        192.0270                10.7                    \-          1.2
  Citrulline                   C6H13N3O3     175.0956                17.17                   2.7         2.2
  Coumarate                    C9H8O3        164.0473                14.40                   26.7        \-
  Creatine                     C4H9N3O2      131.0694                16.62                   576.9       20.5
  Creatinine                   C4H7N3O       113.0589                16.61                   15.6        1.0
  Cystathionine                C7H14N2O4S    222.0674                21.74                   7.4         1.2
  Cysteine                     C3H7NO2S      121.0197                15.30                   2.8         \-
  Cytidine                     C9H13N3O5     243.0855                17.33                   2.1         1.2
  Deoxyfluorouridine           C9H11FN2O5    246.0651                12.20                   \-          6.2
  Dimethylarginine             C8H18N4O2     202.1429                24.45                   1.4         \-
  Dimethylglycine              C4H9NO2       103.0633                17.21                   24.9        \-
  Fumarate                     C4H4O4        116.0109                7.78                    \-          0.8
  Gluconate                    C6H12O7       196.0583                15.64                   \-          43.1
  Glutamate                    C5H9NO4       147.0531                16.17                   79.1        61.6
  Glutamine                    C5H10N2O3     146.0691                16.78                   27.9        95.2
  Glutamyl-glutamate           C10H14N2O7    274.0801                15.61                   8.2         \-
  Glutamyl-leucine             C11H19N2O5    259.1293                15.48                   2.8         \-
  Glutathione                  C10H17N3O6S   307.0838                15.06                   22.8        \-
  Glycerophosphatidylcholine   C8H20NO6P     257.1028                18.06                   42.4        \-
  Glycine                      C2H5NO2       75.0320                 17.13                   2.2         1.3
  Glycolate                    C2H4O3        76.0160                 6.51                    \-          4.5
  Guanidinobutanoate           C5H11N3O2     145.0851                15.73                   8.4         \-
  Guanine                      C5H5N5O       151.0494                11.90                   13.5        7.9
  Guanosine                    C10H13N5O5    283.0916                11.87                   2.3         18.4
  Hexose-deoxy sugar           C6H12O5       164.0679                14.39                   \-          5.2
  Hexose-Phosphate             C6H13O9P      260.0297                14.94                   \-          17.4
  Histidine                    C6H9N3O2      155.0694                25.13                   14.6        6.1
  Hydroxyphenylglycine         C8H9NO3       167.0582                16.61                   \-          0.7
  Hydroxyproline               C5H9NO3       131.0582                16.17                   \-          1.6
  Hypoxanthine                 C5H4N4O       136.0385                9.45                    489.9       108.7
  Indoleacetate                C10H9NO2      175.0633                9.17                    5.0         \-
  Inosine                      C10H12N4O5    268.0807                10.03                   45.7        388.8
  Kynurenine                   C10H12N2O3    208.0847                12.19                   0.9         \-
  Lactate                      C3H6O3        90.0316                 7.57                    \-          6.1
  leucine/Isoleucine           C6H13NO2      131.0946                12.69                   20.3        1.6
  Lysine                       C6H14N2O2     146.1055                26.62                   4.7         16.3
  Lysophosphatidylserine       C24H48NO9P    326.3033                6.89                    4.9         \-
  Malate                       C4H6O5        134.0215                8.66                    \-          9.5
  Malonate                     C3H4O4        104.0109                7.27                    0.4         \-
  Methionine                   C5H11NO2S     149.0510                13.43                   7.3         1.2
  Methyladenosine              C11H15N5O4    281.1124                17.16                   0.9         0.7
  Methylaspartate              C5H9NO4       147.0531                8.39                    48.4        20.3
  Methylbutyroylcarnitine      C12H23NO4     245.1627                11.8                    0.3         \-
  Methylfuranone               C6H8O2        98.0368                 15.66                   \-          223.4
  Methylhistidine              C7H11N3O2     169.0851                25.54                   2.2         \-
  Methylsulfolene              C5H8O2S       132.0245                13.44                   16.9        \-
  Methylthioadenosine          C11H15N5O3S   297.0895                10.61                   1.3         \-
  Methylthiophene              C5H6S         98.0190                 7.80                    1.2         \-
  Myo-inositol                 C6H12O6       180.0633                15.83                   5.3         5.0
  Nicotinamide                 C6H6N2O       122.0480                9.57                    104.8       \-
  Nicotinate                   C6H5NO2       123.0320                9.14                    \-          0.6
  Ornithine                    C5H12N2O2     132.0898                26.39                   0.5         14.4
  Oxoproline                   C5H7NO3       129.0425                16.77                   217.42      30.2
  Pantothenate                 C9H17NO5      219.1106                6.74                    10.1        2.2
  Pentose sugar                C5H10O5       150.0528                13.55                   \-          10.7
  Phenylalanine                C9H11NO2      165.0789                12.03                   9.2         0.4
  Phosphatidylcholine          C40H80NO8P    733.5621                9.08                    63.6        \-
  Phosphenolpyruvate           C3H5O6P       167.9823                12.09                   \-          0.4
  Phosphocreatine              C4H10N3O5P    211.0358                15.05                   4.1         \-
  Pipecolate                   C6H11NO2      129.0789                14.76                   1.7         \-
  Proline                      C5H9NO2       115.0633                14.99                   30.2        0.3
  Propionylcarnitine           C10H19NO4     217.1314                12.92                   1.3         \-
  Putrescine                   C4H12N2       88.1000                 34.8                    \-          0.8
  Riboflavin                   C17H20N4O6    376.1382                7.9                     5.5         \-
  Serine                       C3H7NO3       105.0425                17.06                   4.2         1.9
  Spermidine                   C7H19N3       145.1578                30.46                   1.1         \-
  Taurine                      C2H7NO3S      125.0146                15.00                   119.9       286.3
  Thiouracil                   C4H4N2OS      128.0044                8.4                     \-          0.9
  Threonine/Homoserine         C4H9NO3       119.0582                16.37                   6.9         \-
  Thymidine                    C10H14N2O5    242.0902                8.2                     \-          1.6
  Thymine                      C5H6N2O2      126.0429                9.30                    0.6         25.6
  Tocopherol                   C29H50O2      430.3810                20.89                   5.1         \-
  Tryptophan                   C11H12N2O2    204.0898                12.74                   4.2         1
  Tyrosine                     C9H11NO3      181.0738                14.39                   8.8         14.9
  Uracil                       C4H4N2O2      112.0272                9.14                    27.3        6.3
  Urate                        C5H4N4O3      168.0283                11.19                   2.3         3.8
  Uridine                      C9H12N2O6     244.0695                9.18                    1.7         12.1
  Valine                       C5H11NO2      117.0789                14.66                   4.6         0.9
  Xanthine                     C5H4N4O2      152.0334                8.88                    78.1        51.7
  Xanthosine                   C10H12N4O6    284.0756                11.85                   \-          2.8
  Xanthurenate                 C10H7NO4      205.0375                11.20                   1.4         \-

Annotations were made by matching fragmentation of analyte peaks to fragmentations in publicly accessible databases. Displaying the molecular formula, molecular weight in daltons, retention time in minutes and intensity in positive and negative ionisation modes in arbitrary units for all metabolites.---represents metabolites not detected in this ionisation mode.

10.1371/journal.pone.0122883.t006

###### Metabolites annotated from the reversed phase method.

![](pone.0122883.t006){#pone.0122883.t006g}

  Name                   Formula            Molecular Weight (Da)   Retention time (Mins)   Intensity   
  ---------------------- ------------------ ----------------------- ----------------------- ----------- -------
  Docosahexaenoic acid   C22H32O2           328.2400                5.02                    \-          16.8
  Hexadecynyl acetate    C18H32O2           280.2388                4.61                    \-          1.7
  Hydroxycholestanol     C27H48O2           404.3636                15.06                   \-          3.7
  DG(40:5)               C43H74O5           670.5536                20.79                   1.8         \-
  DG(34:2)               C37H68O5           592.5066                27.07                   0.7         \-
  DG(42:3)               C45H82O5           702.6162                17.58                   3.9         \-
  DG(37:2)               C40H74O5           634.5536                27.14                   1.2         \-
  SM(d34:1)              C39H80N2O6P        703.5753                13.20                   0.7         \-
  SM(41:2)               C46H92N2O6P        799.6693                25.84                   4.6         
  SM(d41:1)              C46H94N2O6P        801.6849                18.55                   1.9         \-
  SM(d42:1)              C47H96N2O6P        815.7006                24.13                   3.9         \-
  SM(d43:2)              C48H96N2O6P        827.7006                20.20                   18.9        \-
  Creatine 16:1 OH       C39H77N2O7P        716.5468                16.53                   \-          10.2
  TG(52:7)               C55H92O6           848\. 6893              28.10                   6.2         \-
  TG(52:3)               C55H100O6          856.7519                19.44                   1.4         \-
  TG(48:3)               C51H92O6           800.6823                17.70                   2.3         \-
  TG(50:3)               C53H96O6           828.7112                19.97                   1.1         \-
  TG(54:7)               C57H96O6           876.7199                30.36                   3.1         \-
  TG(54:6)               C57H98O6           878.7420                30.43                   1.1         \-
  TG(56:7)               C59H98O6           902.7421                32.71                   1.2         \-
  PI(34:1)               C43H81O13P         836.5414                12.32                   73.1        \-
  PI(36:3)               C45H81O13P         860.5414                21.29                   \-          6.93
  PI(32:0)               C41H79O13P         810.5258                20.97                   \-          19.00
  PI(38:2)               C47H87O13P         891.1596                19.08                   \-          34.13
  PI(40:5)               C49H85O13P         912.5727                16.31                   3.2         
  PI(38:5)               C~47~H~81~O~13~P   884.5414                23.33                   7.2         \-
  PA(36:2)               C39H73O8P          700.9659                15.97                   1.4         \-
  PA(34:1)               C37H71O8P          674.9286                20.68                   32.8        \-
  PA(39:0)               C42H85O7P          732.6091                14.89                   0.9         \-
  PA(34:2)               C37H69O8P          672.4730                20.33                               
  GluCer(36:1)           C42H81NO8          727.5962                24.19                   5.2         \-
  GluCer(d40:1)          C46H89NO8          783.6588                23.02                   16.7        \-
  GluCer(d40:2)          C46H87NO8          781.6351                23.60                   1.1         4.3
  GluCer(42:2)           C48H91NO8          809.6744                19.18                   1.8         \-
  PC(31:2)               C39H74NO8P         715.5134                18.85                   2.4         \-
  PC(36:2)               C44H84NO7P         770.7432                18.36                   1.5         \-
  PC(33:2)               C41H78NO8P         743.5492                20.21                   1.7         12.1
  PC(32:3)               C42H74NO8P         751.5152                18.77                   \-          57.7
  PC(33:1)               C41H80NO8P         745.5574                21.30                   \-          0.3
  PC(37:6)               C45H78NO8P         791.5417                19.61                   \-          1.9
  PC(32:2)               C40H76NO8P         729.5322                15.98                   13.7        \-
  PC(38:9)               C46H74NO8P         799.5298                19.11                   \-          45.4
  PC(35:0)               C43H86NO8P         775.6091                15.75                   0.71        
  PC(35:6)               C43H74NO8P         763.5146                18.70                   2.3         22.4
  PC(35:3)               C43H80NO8P         769.5688                20.70                   41.5        \-
  PC(35:6)               C43H74NO8P         763.5146                17.63                   2.1         \-
  PC(35:3)               C43H80NO8P         769.5688                25.57                   1.5         \-
  PC(36:3)               C44H82NO8P         783.5663                15.49                   15.7        \-
  PC(P-38:5)             C46H82NO7P         791.5828                14.78                   0.5         \-
  PC(44:1)               C52H103NO8P        900.7242                24.05                   19.9        \-
  PC(P-38:6)             C46H80NO7P         789.5609                18.20                   1.0         \-
  PC(44:0)               C52H105NO8P        902.7421                28.94                   18.6        \-
  PC(45:0)               C53H107NO8P        916.6589                27.84                   11.5        \-
  PC (38:0)              C46H92NO8P         817.6561                26.70                   3.2         \-
  PC (40:1)              C48H94NO8P         843.6717                20.24                   6.6         6.4
  PC (40:6)              C48H84NO8P         833.5935                18.78                   1.5         68.1
  PC (38:6)              C44H76NO8P         805.5622                15.60                   16.8        \-
  PC (40:2)              C48H92NO8P         841.6560                21.07                   \-          3.6
  PG(34:1)               C40H77O10P         748.5254                14.43                   3.0         \-
  PG(38:3)               C44H81O10P         800.5567                17.50                   14.8        \-
  PG(36:2)               C42H79O10P         774.5410                17.53                   1.4         \-
  PG(42:0)               C48H97O9P          848.6842                19.75                   2.7         \-
  PE(35:0)               C40H80NO8P         733.5621                13.31                   1.3         
  PE(40:6)               C45H78NO8P         791.5417                19.61                   \-          31.3
  PE(33:1)               C38H74NO8P         703.5158                16.54                   24.6        \-
  PE(35:2)               C40H80NO8P         729.5308                25.83                   4.9         \-
  PE(38:3)               C43H80NO8P         769.5688                25.96                   24.2        \-
  PE(33:2)               C38H72NO8P         701.4996                18.18                               36.9
  PE(34:2)               C39H74NO8P         715.5134                18.85                   \-          12.4
  PE(36:4)               C41H76NO8P         739.5154                12.76                   0.1         \-
  PE(36:2)               C41H78NO8P         743.5492                14.70                   2.4         \-
  PE(36:5)               C41H72NO8P         737.4995                21.03                   2.5         \-
  PE(36:1)               C41H76NO8P         745.5574                20.23                   \-          0.3
  PE(38:6)               C43H74NO8P         763.5156                18.70                   12.2        \-
  PE(38:4)               C43H78NO8P         768.0551                23.40                   6.4         \-
  PE(46:1)               C51H100NO8P        885.7367                22.07                   7.6         \-
  PE(O-36:0)             C41H86NO6P         719.6105                12.32                   0.1         \-
  PE(40:2)               C45H86NO8P         799.6091                16.03                   1.0         \-
  PE(44:8)               C49H82NO8P         844.5151                19.64                   3.2         \-
  LPC(18:2)              C26H50NO7P         519.3324                12.10                   2.8         
  LPC(20:4)              C28H50NO7P         543.3353                11.80                   3.1         \-
  LPC(24:1)              C32H64NO7P         605.4384                9.13                    2.1         \-
  LPA(18:0)              C21H43O7P          438.2746                15.97                   0.9         
  LPE(22:0)              C27H56NO7P         537.7098                15.76                   \-          10.1
  LPE(24:1)              C29H58NO7P         563.7471                16.41                   \-          7.2
  PS(30:1)               C36H68NO10P        705.4580                18.33                   0.3         \-
  PS(38:3)               C44H80NO10P        813.5519                21.55                   \-          1.9
  PS(40:5)               C46H80NO10P        837.5519                12.44                   0.7         \-
  PS(37:3)               C43H78NO10P        799.5298                10.64                   \-          1.5
  PS(36:1)               C42H80NO10P        789.5609                13.75                   0.8         \-
  PS(36:0)               C42H82NO10P        791.5800                14.77                   0.4         \-
  PS(36:5)               C42H72NO10P        781.9955                12.70                   1.1         \-
  PS(0--34:0)            C40H80NO9P         749.5511                14.55                   0.3         \-
  PS(34:1)               C40H76O10P         761.5975                16.88                   1.3         \-
  Cer(36:1)              C36H67NO3          565.5435                17.49                   \-          8.6
  Cer(38:1)              C38H67NO3          593.5745                19.16                   \-          2.7
  Cer(40:1)              C40H67NO3          621.6163                20.60                   \-          1.9
  Cer(42:1)              C42H83NO3          649.6372                20.83                   \-          1.2
  Cer(d44:2)             C44H85NO3          675.6477                24.30                   5.6         \-
  Cer(d40:1)             C40H80NO6P         701.5575                15.13                   3.8         \-

Annotations were made by matching fragmentation of analyte peaks to fragmentations in publicly accessible databases. Displaying the molecular formula, molecular weight in daltons, retention time in minutes and intensity in positive and negative ionisation modes in arbitrary abundance units for all metabolites.---represents metabolites not detected in this ionisation mode. **Abbreviations:** Lysophosphatidylcholines (LPC), Lysophosphatidylethanolamines (LPE),Phosphatidic acids (PA), Phosphatidylcholines (PC), Ether-linked phosphatidylethanolamines (PE-O), Phosphatidylglycerols (PG), Phosphatidylinositols (PI), Phosphatidylserines (PS), Ether-linked phosphatidylserines(PS-O), Ether-linked phosphatidylserines (PS-O), Sphingomyelins (SM), Dihydroxy-glucosylceramide (GluCer-d), Dihydroxyceramide (Cer-d), Triacylglycerols (TG), Diacylglycerols (DG).

Conclusions {#sec015}
===========

The method described in this paper is shown to be capable of measuring over 4,000 metabolite features from as little as 3mg of tissue with a high degree of reproducibility of which we were able to annotate 200 metabolites from a variety of metabolite classes across a range of concentrations. It is hoped that the low required sample mass and improved sensitivity of this method will provide a valuable tool to analyse cerebral metabolism, hopefully providing new insights into the functioning of the brain as well as the mechanisms of pathology of neurological disorders.

Supporting Information {#sec016}
======================

###### Measured metabolite features in the HILIC method in experiment 2.

Showing the number of metabolite peaks identified and their relative variability in 100%, 93%, 87%, 80% and 73% of 15 sample replicates after transformation based on the recovery of both internal standards. ^a^ percentage of samples a peak is detected in, ^b^ coefficient of variance of peak intensity between samples.
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Click here for additional data file.
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